SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel's stock is surging amid reports of potential investments and partnerships with major players like Apple and TSMC, building on momentum from a recent deal with Nvidia. The community is buzzing about the possibilities of these collaborations, viewing them as a sign of a significant turnaround for the chipmaker. With government backing and strategic moves underway, investors are closely watching Intel's next steps in the evolving semiconductor landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies, viewing the current dip as a buying opportunity before the next leg up. Active community members emphasize the project's ongoing developments, listings on multiple exchanges, and upcoming utilities, highlighting the development team's transparency and commitment. A buy contest is currently underway to push the price to the next milestone.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as discussions highlight its potential to be the next PEPE, a popular meme coin, particularly within the Solana ecosystem. Community members are enthusiastic about its availability on Phantom Wallet and are closely watching its chart for bullish signals, anticipating a significant breakout.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Despite a recently announced hosting deal backed by Google, Cipher Mining is trending downwards, leading to discussions about dilution from a convertible note offering. The community is debating whether this dip is a buying opportunity, given the company's move into AI data centers and long-term growth potential, or a sign of market overvaluation. Some investors believe the long-term AI prospects and Google's involvement outweigh short-term concerns.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW.X) is trending as the community highlights its multichain functionality across Solana, BSC, Cronos, and Ethereum, with a built-in burn mechanism. Community members are emphasizing its organic growth, strong community, and the deflationary nature of the token. Bullish sentiment is high as some users encourage buying the dip.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive ($DRV.X) is trending amid news of a potential collaboration with Synthetix to develop derivatives on the Ethereum network. The crypto community is actively discussing the possible implications of this partnership and anticipating future developments. Mentions of other cryptos, such as Bitcoin and Ethereum, suggest a broader interest in the derivatives space.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as the community rallies around the meme coin, expressing strong bullish sentiment and anticipating potential listings on major exchanges. The coin's association with the popular 'Rage Guy' meme and comparisons to other meme coins like TROLL are fueling discussions. Investors are actively encouraging community participation and further 'RAGING' to drive the coin's visibility.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending due to FDA approval for its oral acromegaly drug, PALSONIFY, sparking excitement among traders who anticipate a significant price movement. The community is focused on the potential for a short squeeze, given the high institutional ownership and short interest. Trading was halted following the news, adding to the speculation and anticipation.

Skywater Technology, Inc. is a holding company. It engages in the provision of semiconductor development, manufacturing services, and packaging services. The company was founded on October 3, 2016 and is headquartered in Bloomington, MN.

SkyWater Technology Inc

SkyWater Technology ($SKYT) is trending as discussions revolve around its potential in the semiconductor and quantum computing sectors, with community members highlighting upcoming revenue growth and government support. Some see catalysts related to quantum partnerships and domestic supply chain deals, while others discuss institutional ownership and technical analysis. Despite positive sentiment, concerns remain regarding potential government shutdowns and management decisions.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax ($KMX) is trending due to disappointing Q2 results, including a slump in car sales and rising loan loss provisions, leading to a breach of its 52-week low. The community is discussing whether the stock is now a bargain or if it signals broader issues in the auto industry, especially compared to competitors like Carvana. Some investors see the dip as an overreaction and buying opportunity, while others worry about debt and economic headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. President Donald Trump said on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting Oct. 1 unless manufacturers are actively building plants in the country.&nbsp;As part of a series of late-night posts on Truth Social on Thursday,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">Trump said</a> the exemption will apply only to firms that have “broken ground” or are “under construction.” “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”&nbsp;The announcement intensifies the administration’s push to shift drug manufacturing to the U.S. Last month, Trump said the U.S. would begin with a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">“small tariff”</a> on imported drugs before raising duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had previously been exempt from Trump’s reciprocal tariff program; however, the new duties will apply to prescription drugs, biologics, specialty medicines, and over-the-counter products, except for generic drugs, which remain excluded.Major drugmakers have responded unevenly.&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> has committed more than $50 billion since 2020 to U.S. expansion, including $27 billion for four new “mega sites.” The company supports maintaining the U.S. as the “world’s leading destination for biopharmaceutical research and manufacturing” and agrees with the administration’s goal of more fairly sharing drug costs across developed countries, even as it warns that broad tariffs could raise costs and limit access.Lilly’s stream on Stocktwits gained traction late Thursday after Trump’s announcement, with sentiment tilting ‘bullish’ as retail traders bet that the company would benefit from the latest federal policy. “$LLY did great with plant announcement in houston this week. They wont have tariffs,”&nbsp;<a href="https://stocktwits.com/Gorohanada/message/630073275">said</a> one user.Several users noted that Novo Nordisk, Regeneron and Thermo Fisher also have U.S. sites that could qualify. Some argued investors misunderstand Novo’s footprint, contributing to its recent weakness despite likely exemptions.<stembedurl>https://stocktwits.com/3rdtimeretired/message/630071784</stembedurl><stembedurl>https://stocktwits.com/Bullish_Trader555/message/630067344</stembedurl><stembedurl>https://stocktwits.com/oldmanrizzer/message/630072277</stembedurl>AstraZeneca and Roche each announced plans this summer to invest $50 billion in new or expanded facilities across multiple states. Merck has invested more than $12 billion in U.S. manufacturing since 2017 and plans to invest an additional $9 billion by 2028, while Biogen has pledged $2 billion to upgrade its North Carolina plants.Others have taken a more cautious stance. Pfizer stated in March that it could shift overseas production to existing U.S. sites if necessary, but has not committed to new investment, whereas Novo Nordisk has yet to announce major U.S. projects.&nbsp;Trump’s Thursday night post followed the launch of fresh national security probes into imports of robotics, industrial machinery, and medical devices. The Commerce Department said on Wednesday that it launched investigations on Sept. 2 to determine if these imports could pose a risk to U.S. national security.&nbsp;On Stocktwits, retail sentiment for the SPDR S&amp;P Biotech ETF (XBI) was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/XBI">XBI</a> has risen 6.5%. So far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.

Equity

AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?

AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.

Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

Eli Lilly &amp; Co. (LLY) has halted a study of its drug Bimagrumab, alone or in combination with its approved weight-loss drug Tirzepatide, in patients with obesity.A U.S. registry of clinical trials <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://clinicaltrials.gov/study/NCT06901349">indicates</a> that the study has been terminated due to strategic business reasons without elaboration.The purpose of the study was to see how well and how safely Bimagrumab, Tirzepatide, and the combination worked in lowering body weight in participants with obesity or overweight and type 2 diabetes. Tirzepatide is the active ingredient in the company’s popular obesity drug Zepbound. While the primary goal of the study was weight loss, the company also sought to identify the change in body fat mass associated with the drug.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-25/lilly-halts-diabetes-trial-of-muscle-sparing-drug-with-zepbound">first</a> reported the termination of the trial. Following the development, the stock traded nearly 1% lower in Thursday’s pre-market session.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Lilly closed the mid-stage trial on June 10, after starting it in May, according to the registry. The study had 50 locations in the U.S. and abroad and was supposed to last about 13 months. Lilly gained access to Bimagrumab through its $1.925 billion acquisition of privately held Versanis Bio, which was completed in August 2023.A parallel study in obese patients without diabetes remains active, Bloomberg noted.Eli Lilly <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-s-newest-obesity-drug-candidate-stirs-wall-street-buzz-but-not-everyone-s-sold/chmJdk1RR3q">said</a> in June that patients who took the highest dose of Bimagrumab alongside rival Novo Nordisk’s Semaglutide lost more fat mass than those on Semaglutide alone in a trial.LLY stock is down 4% this year and approximately 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evaxion-stock-makes-whopping-jump-pre-market-after-outlicensing-vaccine-candidate/chDl7l1R34i">Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Terminates A Study Of Bimagrumab In Obesity

A U.S. registry of clinical trials shows that the study has been terminated for strategic business reasons.

LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?

Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.

The Zacks Analyst Blog Highlights Apple, Eli Lilly, Chevron and Monarch Cement

Apple, Eli Lilly, Chevron, and Monarch Cement show mixed performance, with growth in services, strong drug demand and strategic acquisitions.

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? 

Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR). 

Eli Lilly (LLY) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the preceding trading day.

Top Analyst Reports for Apple, Eli Lilly & Chevron

Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.

Eli Lilly and Company (LLY) announced on Tuesday that it plans to construct a new $ 6.5 billion manufacturing facility in Texas as part of its efforts to expand domestic medicine production.The new facility, located at Generation Park in Houston, marks the second of four new U.S. sites that Lilly intends to announce this year.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lilly-plans-to-build-a-new-6-5-billion-facility-to-manufacture-active-pharmaceutical-ingredients-in-texas-302563621.html">stated</a> that the Houston facility will be operational within five years and will focus on manufacturing the company's pipeline of small molecule medicines across various therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience. The company also said that the site will be among those that manufacture its much-awaited oral obesity drug Orforglipron. Lilly expects to make regulatory submissions for Orforglipron in the treatment of obesity by the end of this year."Our new Houston site will enhance Lilly's ability to manufacture Orforglipron at scale and, if approved, help fulfill the medicine's potential as a metabolic health treatment for tens of millions of people worldwide who prefer the ease of a pill that can be taken without food and water restrictions," said CEO David A Ricks.According to Lilly, the new facility will bring 615 new high-wage jobs to the Greater Houston area, including engineers, scientists, and lab technicians, in addition to 4,000 construction jobs. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within ‘bearish’ territory while message volume fell from ‘normal’ to ‘low’ levels.In February, Lilly announced its plans to bolster its domestic medicine production by building four new pharmaceutical manufacturing sites in the U.S., bringing the company’s total U.S. capital expansion commitments to more than $50 billion since 2020.While three of the facilities will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis, and further strengthening Lilly's supply chain, the fourth will extend the company's global parenteral manufacturing network for future injectable therapies, the company had said.Last week, the company also <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">announced</a> plans for a $5 billion manufacturing facility in Virginia.LLY stock is down 3% this year and approximately 19% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ionis-pharma-stock-rises-after-multiple-price-target-hikes/chDLGmZR35v">Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas

The new facility, located at Generation Park in Houston, marks the second of four new U.S. sites that Lilly intends to announce this year.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$6.36	--	--	N/A
Q2 '25	$5.60	$6.31	12.70%	BEAT
Q1 '25	$3.26	$3.34	2.51%	BEAT
Q4 '24	$5.01	$5.32	6.15%	BEAT
Q3 '24	$1.45	$1.18	-18.79%	MISSED

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest LLY News

LLY Lilly(Eli) & Co